PDCD1 and breast cancer: The work presented in this study is the first, to our knowledge, to characterize a panel (PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM3) of targetable inhibitory immune checkpoint molecules in primary BC.